Guggenheim Capital LLC cut its position in shares of Chemours Co (NYSE:CC) by 58.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 169,917 shares of the company’s stock after selling 243,237 shares during the period. Guggenheim Capital LLC’s holdings in Chemours were worth $3,753,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. LS Investment Advisors LLC boosted its stake in shares of Chemours by 3.9% in the third quarter. LS Investment Advisors LLC now owns 6,997 shares of the company’s stock worth $112,000 after buying an additional 265 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Chemours during the third quarter worth $124,000. MSI Financial Services Inc boosted its stake in shares of Chemours by 188.6% in the third quarter. MSI Financial Services Inc now owns 8,094 shares of the company’s stock worth $129,000 after buying an additional 5,289 shares in the last quarter. Creative Planning boosted its stake in shares of Chemours by 33.5% in the third quarter. Creative Planning now owns 10,677 shares of the company’s stock worth $171,000 after buying an additional 2,678 shares in the last quarter. Finally, Advisors Preferred LLC purchased a new stake in shares of Chemours during the third quarter worth $177,000. Institutional investors own 74.71% of the company’s stock.
Chemours Co (NYSE:CC) opened at 32.76 on Wednesday. The firm has a market cap of $6.00 billion, a price-to-earnings ratio of 840.00 and a beta of 3.50. Chemours Co has a one year low of $5.82 and a one year high of $35.79. The company’s 50-day moving average price is $32.06 and its 200-day moving average price is $23.11.
Chemours (NYSE:CC) last released its earnings results on Wednesday, February 15th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by $0.21. Chemours had a return on equity of 81.19% and a net margin of 2.78%. The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.24 billion. On average, analysts anticipate that Chemours Co will post $2.57 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, March 15th. Shareholders of record on Monday, February 27th were issued a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date was Thursday, February 23rd. Chemours’s dividend payout ratio is presently 14.81%.
A number of research analysts have recently issued reports on CC shares. Goldman Sachs Group Inc lowered Chemours from a “buy” rating to a “neutral” rating and boosted their target price for the company from $23.00 to $27.00 in a report on Monday, December 12th. Zacks Investment Research lowered Chemours from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 17th. Susquehanna Bancshares Inc raised Chemours from a “neutral” rating to a “positive” rating and set a $40.00 target price on the stock in a report on Friday, February 17th. Citigroup Inc raised Chemours from a “neutral” rating to a “positive” rating and boosted their target price for the company from $26.00 to $40.00 in a report on Friday, February 17th. Finally, Jefferies Group LLC boosted their target price on Chemours from $25.00 to $35.00 and gave the company a “hold” rating in a report on Wednesday, February 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.95.
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).